Premium
Adenovirus‐mediated intra‐tumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma
Author(s) -
Li Li,
Liu RanYi,
Huang JiaLing,
Liu QiCai,
Li Yan,
Wu PeiHong,
Zeng YiXin,
Huang Wenlin
Publication year - 2005
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.21585
Subject(s) - endostatin , nasopharyngeal carcinoma , genetic enhancement , angiogenesis , cancer research , in vivo , metastasis , adenoviridae , neovascularization , transgene , medicine , viral vector , biology , pathology , immunology , cancer , recombinant dna , gene , radiation therapy , biochemistry , microbiology and biotechnology
The growth and metastasis of nasopharyngeal carcinoma (NPC), one of the most common cancers in southern China, is closely related to neovascularization. Here, we examined whether intra‐tumoral delivery of endostatin gene could lead to long‐term local expression of bioactive endostatin at therapeutic levels. We constructed a recombinant adenoviral vector carrying the human endostatin gene (Ad/hEndo), which expressed high‐level endostatin protein in NPC CNE‐2 cells, and significantly inhibited the proliferation and migration of vascular endothelial cells in vitro . Tumor growth and angiogenesis in NPC CNE‐2 xenografted tumors were significantly inhibited after 5 courses of intra‐tumoral treatment with Ad/hEndo in vivo . Endostatin mRNA in tumor tissues peaked at 1–2 days after intra‐tumoral administration and disappeared within 1 week, whereas the plasma endostatin protein levels peaked at 3 days after administration and lasted 2–3 weeks. The therapeutically relevant endostatin transgene expression was achieved during the course of multiple intra‐tumoral administrations with Ad/hEndo. Multiple injections with adenoviral vectors did not lead to continuous increases of adenovirus neutralizing antibodies in serum. Thus, adenovirus‐mediated intra‐tumoral introduction of the human endostatin gene may form a viable new treatment for NPC, although readministration every 2–3 weeks may be necessary for the best effect. © 2005 Wiley‐Liss, Inc.